Payment overview · 2025
General Payments
$1,755.73
90 reported records · 18 companies
Healthcare provider profile · identity verified
Timothy Miller, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LOW MOOR, VA · NPI 1659343572
Verified facts
What the public records show
CMS Open Payments records show Timothy Miller, PA received $1,755.73 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $335.48 | 19.1% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.85 | 13.2% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $200.77 | 11.4% | 10 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $115.49 | 6.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.55 | 6.2% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.19 | 4.9% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $84.20 | 4.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.82 | 4.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.98 | 4.5% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.95 | 4.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.33 | 3.7% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $63.45 | 3.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.20 | 3.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.40 | 2.9% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.70 | 2.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.77 | 2.4% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.32 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,755.73 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $279.75 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.45 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $182.73 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.11 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $149.50 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $115.49 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.55 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.55 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.19 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $84.20 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $80.82 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $73.95 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.33 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.33 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $63.45 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.40 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.36 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $47.70 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 94 |
| Furosemide | Furosemide | 365 | 105 |
| Omeprazole | Omeprazole | 355 | 90 |
| Gabapentin | Gabapentin | 348 | 94 |
| Potassium Chloride | Potassium Chloride | 340 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 89 |
| Lisinopril | Lisinopril | 318 | 88 |
| Losartan Potassium | Losartan Potassium | 295 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 288 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 281 | 64 |
| Meloxicam | Meloxicam | 272 | 56 |
| Doxycycline Hyclate | Doxycycline Hyclate | 268 | 189 |
| Prednisone | Prednisone | 267 | 167 |
| Alprazolam | Alprazolam | 231 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 62 |
| Metformin Hcl | Metformin Hcl | 197 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 53 |
| Famotidine | Famotidine | 185 | 38 |
| Sertraline Hcl | Sertraline Hcl | 184 | 40 |
| Montelukast Sodium | Montelukast Sodium | 178 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 38 |
| Pregabalin | Pregabalin | 154 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 37 |
| Lorazepam | Lorazepam | 145 | 43 |
| Clonazepam | Clonazepam | 136 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 28 |
| Glipizide Er | Glipizide | 131 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 35 |
| Trazodone Hcl | Trazodone Hcl | 122 | 26 |
| Methylprednisolone | Methylprednisolone | 119 | 97 |
| Simvastatin | Simvastatin | 114 | 31 |
| Eliquis | Apixaban | 108 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 25 |
| Klor-Con M20 | Potassium Chloride | 106 | 39 |
| Tramadol Hcl | Tramadol Hcl | 106 | 44 |
| Metformin Hcl Er | Metformin Hcl | 105 | 26 |
| Allopurinol | Allopurinol | 100 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 94 | 72 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 94 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 22 |
| Ozempic | Semaglutide | 93 | 18 |
| Trulicity | Dulaglutide | 88 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 18 |
| Bumetanide | Bumetanide | 84 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | 17 |
| Glipizide | Glipizide | 81 | 21 |
| Irbesartan | Irbesartan | 80 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 25 |
| Warfarin Sodium | Warfarin Sodium | 79 | 17 |
| Carvedilol | Carvedilol | 76 | 26 |
| Doxepin Hcl | Doxepin Hcl | 73 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 16 |
| Bupropion Xl | Bupropion Hcl | 70 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 16 |
| Diazepam | Diazepam | 63 | 14 |
| Temazepam | Temazepam | 62 | 15 |
| Spironolactone | Spironolactone | 59 | 21 |
| Xarelto | Rivaroxaban | 59 | 11 |
| Synthroid | Levothyroxine Sodium | 58 | 12 |
| Alendronate Sodium | Alendronate Sodium | 57 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Cefdinir | Cefdinir | 54 | 45 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Azithromycin | Azithromycin | 53 | 47 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Glimepiride | Glimepiride | 51 | 15 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Topiramate | Topiramate | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 12 |
| Levofloxacin | Levofloxacin | 47 | 38 |
| Atenolol | Atenolol | 46 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Lovastatin | Lovastatin | 44 | 14 |
| Mupirocin | Mupirocin | 44 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | 11 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Methocarbamol | Methocarbamol | 41 | 18 |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Fluconazole | Fluconazole | 36 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 32 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 19 |
| Cephalexin | Cephalexin | 34 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Nystatin | Nystatin | 28 | 18 |
| Valsartan | Valsartan | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 13 |
| Felodipine Er | Felodipine | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Colchicine | Colchicine | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,755.73 · 90 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, REPATHA, REXULTI, Rybelsus, TONMYA, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error